The PPARs: From Orphan Receptors to Drug Discovery
The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTThe PPARs: From Orphan Receptors to Drug Discovery†Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach, and Brad R. HenkeView Author Information Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709 Cite this: J. Med. Chem. 2000, 43, 4, 527–550Publication Date (Web):February 24, 2000Publication History Received8 November 1999Published online24 February 2000Published inissue 1 February 2000https://pubs.acs.org/doi/10.1021/jm990554ghttps://doi.org/10.1021/jm990554greview-articleACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views6740Altmetric-Citations1452LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Agonists,Ligands,Lipids,Receptors,Rodent models Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is an extremely selective PPARα agonist (subtype selectivity > 5000-fold for PPARγ and > 11,000-fold for PPARδ, respectively) [49, 50].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
In the citing paper
“The PPARα activation by pemafibrate was > 2500 times stronger than fenofibric acid, the active form of fenofibrate.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
Citations
Cites
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Self-citationA Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Research works printed but not linked: 124
- Lichtenstein A. H., 1998, Nutr. Rev., 56, S28
- Harris M. I., 1998, Diabetes Care, 21, 524
- Howard B. V., 1995, Int. Congr. Ser.
- Barzilai N., 1999, J. Gerontol., Ser. A, 54, B96
- Lichtenstein A. H., 1999, Nutr. Rev., 57, 14
- Jump D. B., 1999, Annu. Rev. Nutr., 19, 90
- Mangelsdorf D. J., 1995, Cell, 83, 850
- A, 1999, Cell, 97, 163
- Xu H. E., 1999, Mol. Cell, 3, 403
- Hu E., 1996, Science, 274, 2103
- Zhang B., 1996, J. Biol. Chem., 271, 31774
- Adams M., 1997, J. Biol. Chem., 272, 5132
- Camp H. S., 1999, Endocrinology, 140, 397
- Juge-Aubry C. E., 1999, J. Biol. Chem., 274, 10510
- McDonnell D. P., 1993, Bio/Technology, 11, 1261
- Lehmann J. M., 1995, J. Biol. Chem., 270, 12956
- Xu L., 1999, Curr. Opin. Genet. Dev., 9, 147
- Zhu Y., 1996, Gene Expression, 6, 195
- Dowell P., 1997, J. Biol. Chem., 272, 33443
- Zhu Y., 1997, J. Biol. Chem., 272, 25506
- Yuan C.-X., 1998, Proc. Natl. Acad. Sci. U.S.A., 95, 7944
- Treuter E., 1998, Mol. Endocrinol., 12, 881, 10.1210/mend.12.6.0123 · doi:10.1210/mend.12.6.0123 · Paper page
- Krey G., 1997, Mol. Endocrinol., 11, 791, 10.1210/mend.11.6.0007 · DOI · Paper page
- Zhou G., 1998, Mol. Endocrinol., 12, 1604, 10.1210/mend.12.10.0176 · doi:10.1210/mend.12.10.0176 · Paper page
- Berger J., 1996, Endocrinology, 137, 4195
- Young P. W., 1998, J. Pharmacol. Exp. Ther., 284, 759
- Bell A. R., 1998, Biochem. J., 332, 693
- Heuvel J. P. V, 1999, Toxicol. Sci., 47, 8
- Palmer C. N. A., 1998, Mol. Pharmacol., 53, 22
- Gervois P., 1999, Mol. Endocrinol., 13, 1549
- Gaw A., 1994, Handb. Exp. Pharmacol., 109, 348
- Brown P. J., 1997, Synthesis, 778, 782
- Brown P. J., 1999, J. Med. Chem., 42, 3788
- Forman B. M., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 4317
- Yu K., 1995, J. Biol. Chem., 270, 23983
- Palmer C. N. A., 1994, J. Biol. Chem., 269, 18089
- Lee S. S.-T., 1995, Mol. Cell. Biol., 15, 3022
- Peters J. M., 1997, J. Biol. Chem., 272, 27312
- Gaw A., 1999, Lipoproteins Health Dis., 1145, 1160
- Ross S. D., 1999, Arch. Intern. Med., 159, 1802
- Oliver M. F., 1984, Lancet, 2, 604
- Rutolo G., 1998, J. Am. Coll. Cardiol., 32, 1656
- Libby P., 1999, Mol. Basis Cardiovasc. Dis., 349, 366
- Spencer N. F. L., 1997, Int. Immunol., 9, 1588
- Delerive P., 1999, J. Biol. Chem., 45, 32054
- Vazquez M., 1995, Br. J. Pharmacol., 116, 2075
- Jacobsson A., 1985, J. Biol. Chem., 260, 16254
- Krook A., 1998, Diabetes, 47, 1531
- Ruyter B., 1997, Biochim. Biophys. Acta, 1348, 338
- Zhu Y., 1993, J. Biol. Chem., 268, 26820
- Greene M. E., 1995, Gene Expression, 4, 299
- Chawla A., 1994, Endocrinology, 135, 800, 10.1210/endo.135.2.8033830 · doi:10.1210/endo.135.2.8033830 · Paper page
- Saladin R., 1999, Cell Growth Differ., 10, 48
- Martin G., 1997, J. Biol. Chem., 272, 28217
- Hofmann C., 1994, Endocrinology, 134, 270, 10.1210/endo.134.1.8275942 · DOI · Paper page
- Tai T.-A. C., 1996, J. Biol. Chem., 271, 29914
- Kelly L. J., 1998, Endocrinology, 139, 4927
- Hulin B., 1996, Curr. Pharm. Des., 2, 102
- Kletzien R. F., 1992, Mol. Pharmacol., 41, 398
- Ibrahimi A., 1994, Mol. Pharmacol., 46, 1076
- Harris P. K. W., 1994, Mol. Pharmacol., 45, 445
- Willson T. M., 1996, J. Med. Chem., 39, 668
- Ide T., 1998, Diabetes Front, 9, 346
- Shinkai H., 1998, J. Med. Chem., 41, 1933
- Reginato M. J., 1998, J. Biol. Chem., 273, 32684
- Reddy K. A., 1999, J. Med. Chem., 42, 3278
- Sohda T., 1984, Chem. Pharm. Bull., 32, 4465
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2126
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2130
- Henke B. R., 1998, Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem
- Collins J. L., 1998, Structure−activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem
- Cobb J. E., 1998, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure−activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5069
- Lehmann J. M., 1997, J. Biol. Chem., 272, 3410
- Verrando P., 1981, Biochim. Biophys. Acta, 663, 265
- Negishi M., 1995, J. Lipid Mediators Cell Signalling, 12, 448
- Narumiya S., 1991, Dev. Oncol., 67, 448
- Ikeda H., 1990, Arzneim.-Forsch., 40, 162
- Horikoshi H., 1994, Annu. Rep. Sankyo Res. Lab., 46, 57
- Prigeon R. L., 1998, J. Clin. Endocrinol. Metab., 83, 823
- Fonseca V. A., 1998, J. Clin. Endocrinol. Metab., 83, 3176
- Spencer C. M., 1997, Drugs, 54, 101
- Kumar S., 1996, Diabetologia, 39, 709
- Gimble J. M., 1996, Mol. Pharmacol., 50, 1094
- Jones S. A., 2000, Mol. Endocrinol., 14, 39, 10.1210/mend.14.1.0409 · doi:10.1210/mend.14.1.0409 · Paper page
- Blumberg B., 1998, Genes Dev., 12, 3205
- Ramachandran V., 1999, Drug Metab. Dispos., 27, 1199
- Yamazaki H., 1999, Drug Metab. Dispos., 27, 1266
- Pumford N. R., 1997, Annu. Rev. Pharmacol. Toxicol., 37, 117
- Miller V. A., 1997, J. Clin. Oncol., 15, 795
- Rizvi N. A., 1999, Clin. Cancer Res., 5, 1664
- Vidal-Puig A. J., 1997, J. Clin. Invest., 99, 2422
- Park K. S., 1997, Diabetes, 46, 1234
- Wu Z., 1998, J. Clin. Invest., 101, 32
- Sreenan S., 1999, Am. J. Physiol., 276, E1129
- Miles P. D. G., 1997, Diabetes, 46, 1683
- Yen C.-J., 1997, Biochem. Biophys. Res. Commun., 241, 274
- Deeb S. S., 1998, Nat. Genet., 20, 287
- Valve R., 1999, J. Clin. Endocrinol. Metab., 84, 3712
- Mori Y., 1998, Biochem. Biophys. Res. Commun., 251, 198
- Ek J., 1999, Diabetologia, 42, 895
- Hamann A., 1999, Eur. J. Endocrinol., 141, 92
- Girard J, 1997, Diabetes Metab., 23, 24
- McKeigue P., 1997, Handb. Hypertens., 17, 934
- Dubey R. K., 1993, Am. J. Physiol., 265, R732
- Zhang H. Y., 1994, Hypertension, 24, 110
- Morikang E., 1997, Am. J. Hypertens., 10, 446
- Law R. E., 1996, J. Clin. Invest., 98, 1905
- Kotchen T. A., 1996, Am. J. Physiol., 270, R666
- Zhang F., 1994, Hypertension, 24, 175
- Su C. G., 1999, J. Clin. Invest., 104, 389
- Ehrmann D. A., 1997, J. Clin. Endocrinol. Metab., 82, 2116
- Minamikawa J., 1998, J. Clin. Endocrinol. Metab., 83, 1820
- Suh N., 1999, Cancer Res., 59, 5673
- Lefebvre A.-M., 1998, Nat. Med., 4, 1057
- Schmidt A., 1992, Mol. Endocrinol., 6, 1641
- Amri E.-Z., 1995, J. Biol. Chem., 270, 2371
- Brooks C. D. W., 1996, J. Med. Chem., 39, 2654
- Brun R. P., 1996, Genes Dev., 10, 984
- Lim H., 1999, Genes Dev., 13, 1574
- He T.-C., 1999, Cell, 99, 345
- Cobb J., 1998, Annu. Rep. Med. Chem., 33, 222
- Sliskovic D. R., 1999, Annu. Rep. Med. Chem., 34, 110
- Belch J. J. F., 1998, Proc. Nutr. Soc., 57, 569
- Woutersen R. A., 1999, Mutat. Res., 443, 127
Cited by
Items 701–800 of 1,003
?-Lipoic acid-based PPAR? agonists for treating inflammatory skin diseases
Venkatraman, M., Chittiboyina, A. G., Meingassner, J. G., Ho, C., Varani, J., Ellis, C. N., AVERY, M. A., Pershadsingh, H. A., Kurtz, T., & Benson, S. C. (2004) · Archives of Dermatological Research · doi:10.1007/s00403-004-0480-5 · Cited by 42
“TZDs are high-affinity ligands for the nuclear receptor, peroxisome proliferator-activated receptor-gamma (PPARg), a transcription factor that regulates genetic programs involved in glucose and lipid homeostasis, energy metabolism, and adipocyte growth and differentiation [2].”
Lipids, Lipoproteins, and Peroxisome Proliferator Activated Receptor–δ
Sprecher, D. L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.08.009 · Cited by 51
Palladium-catalyzed C2-acylation of indoles with aryl and alkyl aldehydes
Yan, X., Shen, Y., Chen, D.-Q., Gao, P., Li, Y.-X., Song, X., Liu, X., & Liang, Y. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.08.025 · Cited by 41
Nakano, S., Inada, Y., Masuzaki, H., Tanaka, T., Yasue, S., Ishii, T., Arai, N., Ebihara, K., Hosoda, K., Maruyama, K., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00340.2006 · Cited by 44
“Thus, it is likely that a significant increase in adiponectin level induced by bezafibrate may be attributable to its PPAR agonistic activity (48) and thus contribute, at least partly, to the improvement of glucose metabolism in db/db mice.”
BackgroundZaręba, I., & Palka, J. A. (2016) · BioFactors · doi:10.1002/biof.1283 · Cited by 41
“PPARc is a ligand-dependent transcription factor [66].”
Montaño‐Loza, A. J., & Corpechot, C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.062 · Cited by 44
Kumar, B. R. P., Baig, N. B. R., Sudhir, S., V, Kar, K., Mandava, K., Pankaj, M., & Nanjan, M. J. (2012) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2012.08.002 · Cited by 41
Felts, A. S., Siegel, B. S., Young, S. M., Moth, C. W., Lybrand, T. P., Dannenberg, A. J., Marnett, L. J., & Subbaramaiah, K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700969c · Cited by 41
Kasuga, J.-I., Yamasaki, D., Araya, Y., Nakagawa, A., Makishima, M., Doi, T., Hashimoto, Y., & Miyachi, H. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.09.001 · Cited by 44
Topical Rosiglitazone Is an Effective Anti-Scarring Agent in the Cornea
Huxlin, K. R., Hindman, H. B., Jeon, K., Bühren, J., Macrae, S. M., DeMagistris, M., Ciufo, D. J., Sime, P. J., & Phipps, R. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070785 · Cited by 43
“PPARs are nuclear receptors that function as transcription factors [37,45] and are best known for their important roles in lipid metabolism [46,47].”
BackgroundInflammation in Atherosclerosis and Diabetes Mellitus
Plutzky, J. (2004) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/b:remd.0000032414.17672.5c · Cited by 49
“Another therapeutic target implicated in both diabetes mellitus and inflammation are peroxisome proliferator activated receptors (PPARs), members of the steroid hormone nuclear receptor family [ 33 ,34].”
BackgroundKasuga, J.-I., Nakagome, I., Aoyama, A., Sako, K., Ishizawa, M., Ogura, M., Makishima, M., Hirono, S., Hashimoto, Y., & Miyachi, H. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.05.023 · Cited by 47
Treating hyperglycemia in type 2 diabetes: new goals and strategies.
Lebovitz, H. E. (2002) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.69.10.809 · Cited by 47
Peroxisome proliferator-activated receptor γ and colorectal cancer
Dai, Y., & Wang, W.-H. (2010) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v2.i3.159 · Cited by 44
Fracchiolla, G., Laghezza, A., Piemontese, L., Tortorella, P., Mazza, F., Montanari, R., Pochetti, G., Lavecchia, A., Novellino, E., Pierno, S., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900941b · Cited by 41
Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPARγ agonism
Patle, C. B., de Lemos, J. A., Wyne, K. L., & McGuire, D. K. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.016 · Cited by 41
Shie, F.-S., Nivison, M., Hsu, P.-C., & Montine, T. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787458399 · Cited by 41
“Ligands for PPARγ include both synthetic compounds and endogenous metabolites with different binding affinities to the receptor [55].”
Background5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists
Koyama, H., Boueres, J. K., Han, W., Metzger, E. J., Bergman, J. P., Gratale, D. F., Miller, D. J., Tolman, R. L., MacNaul, K. L., Berger, J. P., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00257-9 · Cited by 41
John, F. O. (2004) · Frontiers in bioscience · doi:10.2741/1300 · Cited by 42
Miller, A. R., & Etgen, G. J. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.9.1489 · Cited by 43
“Decades after they were discovered, the molecular targets of the fibrates and TZDs were shown to be PPAR-α [19,20] and PPAR-γ [23], respectively.”
BackgroundŠauer, P., Vrana, B., Escher, B. I., Grabic, R., Toušová, Z., Krauss, M. K. V., von der Ohe, P. C., König, M., Grabicová, K., Mikušová, P., et al. (2023) · Environment International · doi:10.1016/j.envint.2023.107957 · Cited by 43
Fettach, S., Thari, F. Z., Hafidi, Z., Tachallait, H., Karrouchi, K., Achouri, M. E., Cherrah, Y., Sefrioui, H., Bougrin, K., & Faouzi, M. E. A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1911854 · Cited by 40
“…therapeutic profile and excellent antidiabetic properties, thiazolidinediones possess some severe side effects, such as weight gain (Fonseca, 2003), plasma-volume expansion, bone related disorders and edema (Berlie et al., 2007; Forman et al., 2000; Okazaki et al., 1999; Willson et al., 2000).”
BackgroundInvestigational PPAR-γ agonists for the treatment of Type 2 diabetes
Savkur, R. S., & Miller, A. R. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.763 · Cited by 43
“The fibrates (clofibrate, fenofibrate and bezafibrate) are known to effectively reduce triglycerides and free fatty acids and increase HDLc in both rodents and humans [17,48].”
BackgroundNakano, S., Nagasawa, T., Ijiro, T., Inada, Y., Tamura, T., Maruyama, K., Kuroda, J., Yamazaki, Y., Kusama, H., & Shibata, N. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00363.x · Cited by 42
Parmenon, C., Guillard, J., Caignard, D., Hennuyer, N., Staels, B., Audinot, V., Boutin, J. A., Dacquet, C., Ktorza, A., & Viaud‐Massuard, M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.01.067 · Cited by 40
PPARγ agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line
Nofziger, C., Brown, K. K., Smith, C. D., Harrington, W. W., Murray, D., Bisi, J., Ashton, T. T., Maurio, F. P., Kalsi, K. K., West, T. A., et al. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00090.2009 · Cited by 40
“Activation of PPAR has been shown to have pleiotropic metabolic and physiological effects, such as improved glucose and lipid control, decreases in inflammatory mediators, effects in the vasculature, antiatherogenic properties, reductions in intra-abdominal and intrahepatic fat as well as intramyocellular lipids, and…”
BackgroundYork, M. M., Abdelrahim, M., Chintharlapalli, S. R., Lucero, S., & Safe, S. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0967 · Cited by 43
Park, C., Ji, H.-M., Kim, S.-J., Kil, S., Lee, J. N., Kwak, S., Choe, S., & Park, R. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2916 · Cited by 42
Kurebayashi, S., Xu, X., Ishii, S., Shiraishi, M., Kouhara, H., & Kasayama, S. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.02.004 · Cited by 46
Different ways to regulate the PPAR$alpha; stability
Blanquart, C., Mansouri, R. M., Fruchart, J., Staels, B., & Glineur, C. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.035 · Cited by 43
Miyachi, H., Nomura, M., Tanase, T., Takahashi, Y., Ide, T., Tsunoda, M., Murakami, K., & Awano, K. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00672-2 · Cited by 40
Li, C., Zheng, K., Chen, Y., He, C., Liu, S., Yang, Y., Li, M., Zeng, X., Wang, L., & Zhang, F. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221114198 · Cited by 40
Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come
Ghonem, N. S., & Boyer, J. L. (2013) · Hepatology · doi:10.1002/hep.26155 · Cited by 38
“, 50, 20, and 60 lM, respectively).(3) Thus, the term ‘‘pan-PPAR’’ agonist is a more-accurate descriptive.”
Liu, K., Xu, L., Berger, J. P., MacNaul, K. L., Zhou, G., Doebber, T. W., Forrest, M. J., Moller, D. E., & Jones, A. B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm048993p · Cited by 39
A Promoter in the Novel Exon of hPPARγ Directs the Circadian Expression of PPARγ
Takahashi, S., Inoue, I., Nakajima, Y., Seo, M., Nakano, T., Yang, F., Kumagai, M., Komoda, T., Awata, T., Ikeda, M., et al. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.2410 · Cited by 39
Genovese, T., Mazzon, E., Paola, R. D., Muià, C., Crisafulli, C., Caputi, A. P., & Cuzzocrea, S. (2005) · Shock · doi:10.1097/01.shk.0000190825.28783.a4 · Cited by 39
“sensitizer rosiglitazone is the most potent and selective PPAR-g agonist (16), and there is a good correlation between the potency of the TZDs as PPAR-g agonists in vitro and their efficacy at lowering glucose levels in vivo (17).”
Background1,3,5-Trisubstituted aryls as highly selective PPARδ agonists
Epple, R., Azimioara, M. D., Russo, R., Bursulaya, B. D., Tian, S., Gerken, A., & Iskandar, M. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.079 · Cited by 39
Ali, I. H., Hassan, R. M., Kerdawy, A. M. E., Abo-Elfadl, M. T., Abdallah, H. M. I., Sciandra, F., & Ghannam, I. A. Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116279 · Cited by 38
Optimal Management of Combined Dyslipidemia: What Have We Behind Statins Monotherapy?
Tenenbaum, A., Fisman, E. Z., Motro, M., & Adler, Y. (2008) · Advances in cardiology · doi:10.1159/000115192 · Cited by 44
New Therapies for Primary Biliary Cirrhosis
Floreani, A., Franceschet, I., Perini, L., Cazzagon, N., Gershwin, M. E., & Bowlus, C. L. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8456-5 · Cited by 38
Goebel, M., Wolber, G., Markt, P., Staels, B., Unger, T., Kintscher, U., & Gust, R. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.102 · Cited by 41
Barlaka, E., Galatou, E., Mellidis, K., Ravíngerová, T., & Lazou, A. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12166 · Cited by 41
Brunetti, L., Loiodice, F., Piemontese, L., Tortorella, P., & Laghezza, A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00885 · Cited by 38
Yang, Z., Roth, K., Agarwal, M., Liu, W., & Petriello, M. C. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108633 · Cited by 40
Kotha, S., Deodhar, D. K., & Khedkar, P. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob01446d · Cited by 38
The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism
Huang, J., Das, S. K., Jha, P., Zoughbi, W. A., Schauer, S., Claudel, T., Sexl, V., Vesely, P. W., Birner‐Gruenberger, R., Kratky, D., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.04.012 · Cited by 42
“Fenofibrate is a serum lipid lowering drug that acts by stimulating PPARα activation [11] and possesses anti-tumorigenic properties against several tumor types [13].”
BackgroundCharacterization of the adipose tissue atrophy induced by peroxisome proliferators in mice
Xie, Y., Yang, Q., Nelson, B. D., & DePierre, J. W. (2002) · Lipids · doi:10.1007/s11745-002-0873-7 · Cited by 36
“Perhaps, however, certain PP, such as clofibrate, can activate both PPARα and PPARγ ( 34 ).”
BackgroundKim, Y., Lasher, C. D., Milford, L. M., Murali, T. M., & Rajagopalan, P. (2010) · Tissue Engineering Part C: Methods · doi:10.1089/ten.tec.2010.0012 · Cited by 37
“21,30,32,33 38”
Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury
Esposito, E., & Cuzzocrea, S. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.581231 · Cited by 39
“PPAR-b/d is a factor in neuronal differentiation, and functions of this receptor in various aspects of neural physiology have been suggested [70].”
BackgroundWei, Z.-L., Petukhov, P. A., Bizik, F., Teixeira, J. C., Mercola, M. A., Volpe, E. A., Glazer, R. I., Willson, T. M., & Kozikowski, A. P. (2004) · Journal of the American Chemical Society · doi:10.1021/ja046386l · Cited by 41
Self-citationLenman, A., & Fowler, C. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707352 · Cited by 38
“…of potency towards PPARg, where the order of potency is rosiglitazone (0.06)4pioglitazone (0.69)Etroglitazone (0.78)EMCC-555 (B1)4ciglitazone (3) (numbers in brackets indicate the EC50 values in mM for the compounds in transactivation assays (Reginato et al., 1998; Willson et al., 1996, 2000).”
BackgroundInfluentialJohnson, T. E., Zhang, X. D., Shi, S., & Umbenhauer, D. R. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.03.004 · Cited by 38
Poleni, P.-E., Bianchi, A., Etienne, S., Koufany, M., Sébillaud, S., Netter, P., Terlain, B. L., & Jouzeau, J. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.10.009 · Cited by 44
Interferon Regulatory Factor-1 Mediates PPARγ-Induced Apoptosis in Vascular Smooth Muscle Cells
Lin, Y., Zhu, X., Mclntee, F. L., Xiao, H., Zhang, J., Fu, M., & Chen, Y. E. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000109170.43400.2f · Cited by 38
Mukherjee, R., Locke, K. T., Miao, B., Meyers, D. S., Monshizadegan, H., Zhang, R., Search, D. J., Grimm, D., Flynn, M. A., O’Malley, K. M., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143271 · Cited by 39
“However, the fibrates are low affinity ligands for PPARα ( EC50s > 10μM) (Willson et al., 2000).”
BackgroundInfluentialKasuga, J.-I., Makishima, M., Hashimoto, Y., & Miyachi, H. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.049 · Cited by 38
Bharathkumar, H., Paricharak, S., Dinesh, K. R., Siveen, K. S., Fuchs, J. E., Rangappa, S., Mohan, C. D., Mohandas, N., Kumar, A. P., Sethi, G., et al. (2014) · RSC Advances · doi:10.1039/c4ra08713e · Cited by 38
Insights into PPARγ Phosphorylation and Its Inhibition Mechanism
Montanari, R., Capelli, D., Yamamoto, K., Awaishima, H., Nishikata, K., Barendregt, A., Heck, A. J. R., Loiodice, F., Fabio Altieri, F., Paiardini, A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00048 · Cited by 37
Peroxisome proliferator-activated receptors
Ziouzenkova, O., Perrey, S., Marx, N., Bacqueville, D., & Plutzky, J. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0063-x · Cited by 37
“Serendipitous subsequent chemical screening identified a class of molecules known as thiazolidinediones (TZDs), which not only were ligands for PPAR-γ, but also insulin sensitizers [ 10 ].”
BackgroundInfluentialBioassay‐guided purification and identification of PPAR α/γ agonists from Chlorella sorokiniana
Chou, Y., Prakash, E., Huang, C., Lien, T., Chen, X., Su, I., Chao, Y., Hsieh, H., & Hsu, J. T. (2008) · Phytotherapy Research · doi:10.1002/ptr.2280 · Cited by 37
“…synthetic ligands, PPARs regulate the expression of target genes involved in a variety of important physiological pathways such as lipid metabolism, insulin sensitivity, cell differentiation, inflammation, proliferation and apoptosis (Willson et al., 2000; Moraes et al., 2006; Zoete et al., 2007).”
BackgroundSundriyal, S., Viswanad, B., Ramarao, P., Chakraborti, A. K., & Bharatam, P. V. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.028 · Cited by 37
Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients
Shukla, D. K., Kaiser, C. C., Stebbins, G. T., & Feinstein, D. L. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.01.046 · Cited by 40
Gomaraschi, M., Fracanzani, A. L., Dongiovanni, P., Pavanello, C., Giorgio, E., Dalt, L. D., Norata, G. D., Calabresi, L., Consonni, D., Lombardi, R., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.158523 · Cited by 41
Sabatini, M., Bardiot, A., Lesur, C., Moulharat, N., Thomas, M., Richard, I., & Fradin, A. (2002) · Osteoarthritis and Cartilage · doi:10.1053/joca.2002.0827 · Cited by 41
Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes
Barbier, O., Fontaine, C., Fruchart, J., & Staels, B. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.07.007 · Cited by 41
Amphipathic 3-Phenyl-7-propylbenzisoxazoles; human pPaR γ, δ and α agonists
Adams, A. D., Yuen, W., Hu, Z., Santini, C., Jones, A. B., MacNaul, K. L., Berger, J. P., Doebber, T. W., & Moller, D. E. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)01029-6 · Cited by 37
Cuzzocrea, S., Paola, R. D., Mazzon, E., Genovese, T., Mui, C., & Caputi, A. P. (2004) · Shock · doi:10.1097/01.shk.0000136704.26372.2d · Cited by 37
“The insulin sensitizer rosiglitazone is the most potent and selective PPAR- agonist (8–10), and there is a good correlation between the potency of the TZDs as PPAR- agonists in vitro and their efficacy at lowering glucose levels in vivo (11).”
BackgroundTakahashi, K., Kamijo, Y., Hora, K., Hashimoto, K., Higuchi, M., Nakajima, T., Ehara, T., Shigematsu, H., Gonzalez, F. J., & Aoyama, T. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.02.012 · Cited by 36
“Since clofibrate is known to be a pan-agonist of PPARα and PPARγ (Willson et al., 2000), the effects of pretreatment by the PPARγ agonist pioglitazone were also examined in these mice.”
BackgroundInfluentialKawashima, A., Harada, T., Imada, K., Yano, T., & Mizuguchi, K. (2008) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2008.07.002 · Cited by 39
Process Development and Scale-Up of PPAR α/γ Dual Agonist Lobeglitazone Sulfate (CKD-501)
Lee, H. W., Ahn, J. B., Kang, S. K., Ahn, S. K., & Ha, D.-C. (2007) · Organic Process Research & Development · doi:10.1021/op060087u · Cited by 36
Liver X Receptor: A novel therapeutic target
Patel, M., Oza, N., Anand, I., Deshpande, S., & Patel, C. (2008) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.41445 · Cited by 41
Tenenbaum, H., Behar, S., Boyko, V., Adler, Y., Fisman, E. Z., Tanné, D., Lapidot, M., Schwammenthal, E., Feinberg, M. S., Matas, Z., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.005 · Cited by 38
Antidiabetic Action of Bezafibrate in a Large Observational Database
Flory, J., Ellenberg, S. S., Szapary, P. O., Strom, B. L., & Hennessy, S. (2009) · Diabetes Care · doi:10.2337/dc08-1809 · Cited by 36
“Studies of the other fibrates (gemfibrozil, fenofibrate, ciprofibrate, and clofibrate) have not shown such effects (8–14), and these drugs are far more selective for PPAR- than bezafibrate (15).”
BackgroundPettersen, J. C., Pruimboom‐Brees, I., Francone, O. L., Amacher, D. E., Boldt, S. E., Kerlin, R. L., & Ballinger, W. E. (2012) · Toxicologic Pathology · doi:10.1177/0192623311431945 · Cited by 36
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome
Vega, G. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00170-x · Cited by 37
“Fenofibrate has been reported to act largely through the PPAR- pathway.(46) Other fibrates such as bezafibrate seemingly also have significant action on PPAR(46); the latter could alter glucose and insulin metabolism as well, reducing insulin resistance.”
BackgroundFaiola, B., Falls, J. G., Peterson, R. A., Bordelon, N. R., Brodie, T. A., Cummings, C. A., Romach, E. H., & Miller, R. T. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn130 · Cited by 38
“Although WY-14,643 is approximately 5- and 14-fold more potent against human and murine PPAR-a, respectively, compared with GW0742, it is weakly active on murine PPAR-c (EC50 of approximately 32lM) and is inactive on murine PPAR-d at 100lM ( Willson et al., 2000 ).”
BackgroundInfluentialYe, J., Frangioudakis, G., Iglesias, M. A., Furler, S. M., Ellis, B. A., Dzamko, N. L., Cooney, G. J., & Kraegen, E. W. (2002) · Endocrinology · doi:10.1210/en.2002-220387 · Cited by 37
Mitofusin 2: A link between mitochondrial function and substrate metabolism?
Emery, J., & Ortiz, R. M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.09.003 · Cited by 37
Chinetti, G., Bouhlel, M. A., Copin, C., Duhem, C., Derudas, B., Neve, B., Noel, B., Eeckhoute, J., Lefèbvre, P., Seckl, J. R., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241364 · Cited by 35
PPARs and the Development of Type 1 Diabetes
Holm, L. J., Mønsted, M. Ø., Haupt‐Jorgensen, M., & Buschard, K. (2020) · PPAR Research · doi:10.1155/2020/6198628 · Cited by 38
“It is involved in regulating fat cell differentiation, lipid storage, and differentiation of monocytes into macrophages [32, 33].”
BackgroundHeppner, T. J., Bonev, A. D., Eckman, D. M., Gomez, M. F., Petkov, G. V., & Nelson, M. T. (2004) · Pharmacology · doi:10.1159/000081070 · Cited by 36
Zhong, X., Xiu, L., Wei, G., Liu, Y.-Y., Su, L., Cao, X., Li, Y., & Xiao, H. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.15 · Cited by 35
Liu, J., Dai, X., Xu, Y., Liu, P., Zhang, Y., Liu, X., Fang, Z., Lin, D.-J., Xiao, R., Huang, R., et al. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9253-x · Cited by 38
“Besides the activating ligands of PPARc (the agonists such as TZDs) the antagonistic PPARc ligands include compounds like GW9662 [5, 6].”
BackgroundDesign and synthesis of oxime ethers of α-acyl-β-phenylpropanoic acids as PPAR dual agonists
Han, H. O., Kim, S. H., Kim, K.-H., Hur, G., Yim, H. J., Chung, H., Woo, S. H., Koo, K. D., Lee, C. S., Koh, J. S., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.050 · Cited by 39
Lin, N., Chen, L., Pan, X., Zhu, Y., Zhang, J., Shi, Y.-Q., & Chen, X. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9542-2 · Cited by 35
Kasturi, S., Surarapu, S., Srinivas, U., Dwivedi, S., Yogeeswari, P., Sigalapalli, D. K., Bathini, N. B., Ethiraj, K. S., & Anireddy, J. S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.072 · Cited by 37
PPAR γ Promotes Growth and Invasion of Thyroid Cancer Cells
Wood, W. M., Sharma, V., Bauerle, K. T., Pike, L. A., Zhou, Q., Fretwell, D. L., Schweppe, R. E., & Haugen, B. R. (2011) · PPAR Research · doi:10.1155/2011/171765 · Cited by 35
“Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily which are ligand-dependent transcription factors that regulate many important physiological processes [1].”
BackgroundA yeast two-hybrid technology-based system for the discovery of PPARγ agonist and antagonist
Chen, Q., Chen, J., Sun, T., Shen, J., Shen, X., & Jiang, H. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.09.004 · Cited by 35
Dan-dan, L. I., Chen, J., Chen, Q., Li, G., Chen, J., Yue, J., Chen, M., Wang, X., Shen, J., Shen, X., et al. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00527.x · Cited by 35
Thiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes
Singh, G., Kumar, R., Desna, D. S., Chaudhary, M., Kaur, C., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998254798231005095627 · Cited by 35
Synthesis and structure–activity relationships of fibrate-based analogues inside PPARs
Giampietro, L., D’Angelo, A., Giancristofaro, A., Ammazzalorso, A., Filippis, B. D., Fantacuzzi, M., Linciano, P., Maccallini, C., & Amoroso, R. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.09.111 · Cited by 34
Identifying Activity Cliff Generators of PPAR Ligands Using SAS Maps
Méndez‐Lucio, O., Pérez‐Villanueva, J., Castillo, R., & Medina‐Franco, J. L. (2012) · Molecular Informatics · doi:10.1002/minf.201200078 · Cited by 34
In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer
Fujita, M., Hasegawa, A., Yamamori, M., & Okamura, N. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0557-6 · Cited by 34
“Abbreviations ERK: Extracellular signal-regulated kinase; JNK: c-Jun N-terminal kinase; MAPK: Mitogen-activated protein kinase; PGZ: Pioglitazone; PPAR: Peroxisome proliferator-activated receptor; PPRE: PPAR response element; TGZ: Troglitazone Acknowledgements Not applicable.”
InfluentialDiscovery of novel PTP1B inhibitors with antihyperglycemic activity
Liu, Z., Chai, Q., Li, Y., Shen, Q., Ma, L., Zhang, L.-N., Wang, X., Li, S., Li, J., Li, J., et al. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.81 · Cited by 34
Fujita, M., Yagami, T., Fujio, M., Tohji, C., Takase, K., Yamamoto, Y., Sawada, K., Yamamori, M., & Okamura, N. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.010 · Cited by 34
“55 lM for the human receptor [30].”
The effects of PPARγ on the regulation of the TOMM40 - APOE - C1 genes cluster
Subramanian, S., Gottschalk, W. K., Kim, S. Y., Roses, A. D., & Chiba-Falek, O. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.01.004 · Cited by 32
Kasuga, J.-I., Yamasaki, D., Ogura, K., Shimizu, M., Sato, M., Makishima, M., Doi, T., Hashimoto, Y., & Miyachi, H. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.001 · Cited by 34
R??os-V??zquez, R., Marzoa‐Rivas, R., Gil-Ortega, I., & Kaski, J. C. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606040-00003 · Cited by 36
PPAR-α Expression Inversely Correlates with Inflammatory Cytokines IL-1β and TNF-α in Aging Rats
Gélinas, D. S., & McLaurin, J. (2005) · Neurochemical Research · doi:10.1007/s11064-005-8341-y · Cited by 40
“Three PPAR isotypes have been identified; PPAR-a, PPAR-c, PPAR-d, each with a high degree of homology but differing in tissue expression ( 7 ).”
BackgroundKuwabara, K., Murakami, K., Todo, M., Aoki, T., Asaki, T., Murai, M., & Yano, J. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.064659 · Cited by 37
Metadata
- Authors
- Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R.
- Affiliations
- Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-02-01
- Volume
- 43
- Issue
- 4
- Pages
- 527-550
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1977666051
- Cited by
- 1,816
- References
- 216
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 27 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 44 · 2016: 37 · 2015: 60 · 2014: 62 · 2013: 52 · 2012: 92
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- peroxisome proliferator-activated receptors, orphan receptors, drug discovery, receptor agonists, ligands, lipid signaling, nuclear receptors
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hyperlipidemias, Hypertension, Inflammation, Ligands, Models, Molecular, Neoplasms, Nuclear Proteins, Obesity, Transcription Factors, Drug Design, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.